Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Haleon PLC ( (GB:HLN) ) just unveiled an announcement.
Haleon plc announced a notification concerning managerial transactions under the UK Market Abuse Regulation. Adrian Morris, the General Counsel, is granted a 3-year option over ordinary shares as part of the 2024 Haleon Share Save Plan, exercisable from February 2028, indicating strategic financial planning within the company.
More about Haleon PLC
Haleon plc is a global leader in consumer health, focusing on delivering better everyday health solutions. The company has a diverse product portfolio across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Notable brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, all rooted in trusted science and innovation.
YTD Price Performance: 21.54%
Average Trading Volume: 21,569,713
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £34.76B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.
